Expert Interview
A Third Look: Discussing the potential of CARVYKTI (ciltacabtagene autoleucel) and the results from the Phase 2 CARTITUDE-2 Cohort D study and the subgroup analysis from the CARTITUDE-4 study in multiple myeloma patients.
Ticker(s): LEGNDr. Nelson Chao, MD
Institution: Duke
- Chief, Division of Cell Therapy in the Department of Medicine
- Research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
